Articles about 'Cystic Fibrosis Trust

The Victor Phillip Dahdaleh Heart and Lung Research Institute is a thriving community of scientists and clinicians, the largest concentration of its kind in Europe, focused on tackling the world's biggest killers.

Pseudomonas aeruginosa – an environmental bacteria that can cause devastating multidrug-resistant infections, particularly in people with underlying lung conditions – evolved rapidly and then spread globally over the last 200 years, probably driven by changes in human behaviour, a new study has found.

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown. It is not clear, however, whether these mutated viruses pose an increased risk to patients or are able to evade the vaccine.

A Cambridge institute dedicated to improving cardiovascular and lung health has received a £16 million gift from Canadian entrepreneur and philanthropist Dr Victor Dahdaleh.

A major new institute opens today, bringing together the largest concentration of scientists and clinicians in heart and lung medicine in Europe.

A study has found that much higher doses of antibiotics are needed to eliminate a bacterial infection of the airways when other microbes are present. It helps explain why respiratory infections often persist in people with lung diseases such as cystic fibrosis despite treatment.

Scientists have been able to track how a multi-drug resistant organism is able to evolve and spread widely among cystic fibrosis patients – showing that it can evolve rapidly within an individual during chronic infection.

World-leading AI technology developed by the Cambridge Centre for AI in Medicine and their colleagues – some of which is being showcased this week at the North American Cystic Fibrosis Conference 2020 – offers a glimpse of the future of precision medicine, and unprecedented predictive power to clinicians caring for individuals with the life-limiting condition.

The University of Cambridge and Royal Papworth Hospital held an official ground-breaking ceremony at the new Heart and Lung Research Institute (HLRI) in Cambridge earlier today. The Institute is based on the Cambridge Biomedical Campus and will create the largest cardiothoracic centre for research, education, industry collaboration, and clinical care in Europe. 

Chris Skidmore, Minister for Universities, Science, Research and Innovation, announced on 10 July 2019 a £30 million award to the University of Cambridge to support the new Cambridge Heart and Lung Research Institute (HLRI).